Search for: "Sanofi-Aventis Deutschland GMBH"
Results 21 - 28
of 28
Sort by Relevance
|
Sort by Date
19 Jun 2011, 3:01 pm
The legal fact here was that the person aggrieved (i.e., adversely affected – see A 107) by the decision was Nutrinova (the food ingredients business of Celanese Ventures GmbH, to which company the relevant business assets had been transferred in July 2002). [read post]
8 Feb 2011, 7:19 am
" Sanofi-Aventis Deutschland GMBH, et. al. v. [read post]
24 May 2009, 10:58 pm
The opposing party, Sanofi-Aventis Deutschland GmbH, was represented by McDonnell Boehnen Hulbert & Berghoff LLP, of Chicago. [read post]
16 Jan 2009, 7:00 am
(IP Dragon) Patent strategies for foreign R&D work in China (Philip Brooks' Patent Infringement Updates) All clichés but still true: Intellectual Property Rights enforcement in China leaves room for improvement (IP Dragon) Recognition and protection of well-known trade marks (International Law Office) Revised Chinese patent law aims at quality, compulsory licensing (Intellectual Property Watch) Zen and the art of intellectual property in China (IP Dragon) Colombia… [read post]
16 Dec 2008, 11:47 pm
In contrast, in Aventis Pharma Deutschland GmbH v. [read post]
15 Jul 2008, 4:57 am
The patent was opposed by several companies involved in commercializing RNA interference (RNAi), including Sanofi-Aventis Deutschland GmbH, Sirna Therapeutics, Nucleonics, Inc., Quark Biotech, and Silence Therapeutics AG. [read post]
9 Jun 2008, 4:50 am
Sanofi-Aventis Deutschland GMBH et al. 2:08-cv-00258; filed June 5, 2008 in the Eastern District of Virginia Declaratory judgment of non-infringement and invalidity of U.S. [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
